| Year ended 31 March | ||||
| 2024 | 2023 | |||
| Continuing operations | Notes | £m | £m | |
Revenue | 5 | |||
Operating profit | 6 | |||
Finance income | 10 | |||
Finance expense | 10 | ( | ( | |
Share of profit/(loss) of joint venture | 22 | ( | ||
| Profit before tax | ||||
Income tax expense | 11 | ( | ( | |
| Profit for the year – continuing operations | ||||
Profit for the year – discontinued operations | 12 | |||
| Profit for the year – total operations | ||||
| Attributable to: | ||||
| Owners of the Company | ||||
| Profit for the year – total operations | ||||
| Earnings per share | Pence | Pence | ||
Continuing operations: | 13 | |||
| – | basic | |||
| – | diluted | |||
Total operations: | 13 | |||
| – | basic | |||
| – | diluted | |||
| Year ended 31 March | |||||
| 2024 | 2023 | ||||
| Notes | £m | £m | |||
| Profit for the year – total operations | |||||
| Other comprehensive income/(expense) | |||||
| Items that have been/may be reclassified to profit or loss: | |||||
(Loss)/gain on currency translation of foreign operations | 24 | ( | |||
Fair value gain/(loss) on net investment hedges | 24 | ( | |||
Fair value loss on net investment hedges transferred to the income statement | 24 | ||||
| Gain on currency translation of foreign operations transferred to the income | statement on sale of a subsidiary | 24 | ( | ||
| Fair value gain on cash flow hedges transferred to the income statement on sale | of a subsidiary | 24 | ( | ||
Net loss on cash flow hedges | 24 | ( | ( | ||
Recycling of cost of hedging | 24 | ||||
Share of other comprehensive income/(expense) of joint venture | 22, 24 | ( | |||
Tax effect of the above items | 11 | ||||
( | ( | ||||
| Items that will not be reclassified to profit or loss: | |||||
| Re-measurement of retirement benefit plans: | |||||
| – | actual return higher/(lower) on plan assets | 31 | ( | ||
| – | net actuarial gain on retirement benefit obligations | 31 | |||
Changes in the fair value of equity investments at fair value through OCI | 18, 24 | ( | |||
Tax effect of the above items | 11 | ( | |||
( | |||||
| Total other comprehensive expense | ( | ( | |||
| Total comprehensive income – total operations | |||||
| Analysed by: | |||||
| – | Continuing operations | ||||
| – | Discontinued operations | 12 | |||
| Total comprehensive income – total operations | |||||
| Attributable to: | |||||
| – | Owners of the Company | ||||
| – | Non-controlling interests | ||||
| Total comprehensive income – total operations | |||||
| At 31 March | |||
| 2023 | |||
| £m | |||
| ASSETS | |||
| Non-current assets | |||
Goodwill and other intangible assets | 19 | ||
| Property, plant and equipment (including right-of-use assets | |||
of £34 million (2023 – £39 million)) | 20 | ||
Investments in joint venture | 22 | ||
Investments in equities | 18 | ||
Retirement benefit surplus | 31 | ||
Deferred tax assets | 11 | ||
Trade and other receivables | 17 | ||
| Current assets | |||
Inventories | 15 | ||
Trade and other receivables | 17 | ||
Current tax assets | 11 | ||
Derivative financial instruments | 29 | ||
Cash and cash equivalents | 16 | ||
| TOTAL ASSETS | |||
| EQUITY | |||
| Capital and reserves | |||
Share capital | 23 | ||
Share premium | 23 | ||
| Capital redemption reserve | |||
Other reserves | 24 | ||
| Retained earnings | |||
| Equity attributable to owners of the Company | |||
| Non-controlling interests | |||
| TOTAL EQUITY |
| At 31 March | At 31 March | ||
| 2024 | 2023 | ||
| £m | £m | ||
| LIABILITIES | |||
| Non-current liabilities | |||
Borrowings (including lease liabilities of £36 million (2023 – £44 million)) | 26 | ||
Retirement benefit deficit | 31 | ||
Deferred tax liabilities | 11 | ||
Provisions | 33 | ||
| Current liabilities | |||
Borrowings (including lease liabilities of £10 million (2023 – £10 million)) | 26 | ||
Trade and other payables | 25 | ||
Provisions | 33 | ||
Current tax liabilities | 11 | ||
Derivative financial instruments | 29 | ||
| TOTAL LIABILITIES | |||
| TOTAL EQUITY AND LIABILITIES |
| Year ended 31 March | ||||
| 2024 | 2023 | |||
| Notes | £m | £m | ||
| Cash flows from operating activities – total operations | ||||
| Profit before tax from total operations | ||||
| Adjustments for: | ||||
| – | depreciation of property, plant and equipment (including right-of-use assets | |||
| and excluding exceptional items) | 20 | |||
| – | amortisation of intangible assets | 19 | ||
| – | share-based payments | 32 | ||
| – | net impact of exceptional income statement items | 8 | ( | ( |
| – | net finance expense | 10 | ||
| – | share of (profit)/loss of joint venture | 22 | ( | |
| – | net retirement benefit obligations | ( | ( | |
| – | other non-cash movements | 27 | ( | ( |
| – | changes in working capital | 27 | ( | |
| Cash generated from total operations | ||||
| Net income tax paid | ( | ( | ||
| Exceptional tax on gain on disposal of Primient | ( | ( | ||
| Interest paid | ( | ( | ||
| Net cash generated from operating activities | ||||
| Cash flows from investing activities | ||||
| Purchase of property, plant and equipment | ( | ( | ||
Acquisition of businesses, net of cash acquired | 35 | ( | ||
Disposal of subsidiary (net of cash) | 12 | |||
| Investments in intangible assets | ( | ( | ||
Purchase of equity investments | 18 | ( | ( | |
Disposal of equity investments | 18 | |||
| Interest received | ||||
Dividends received from joint ventures | 22 | |||
Redemption of shares held in joint venture | 22 | |||
| Net cash (used in)/generated from investing activities | ( |
| Year ended 31 March | |||
| 2024 | 2023 | ||
| Notes | £m | £m | |
| Cash flows from financing activities | |||
Purchase of own shares including net settlement | 23 | ( | ( |
| Cash inflow from additional borrowings | |||
| Cash outflow from repayment of borrowings | ( | ( | |
Repayment of leases | 21 | ( | ( |
Dividends paid to the owners of the Company | 14 | ( | ( |
| Net cash used in financing activities | ( | ( | |
| Cash and cash equivalents | |||
| Balance at beginning of year | |||
Net (decrease)/increase in cash and cash equivalents | 28 | ( | |
Currency translation differences | 28 | ( | |
Balance at end of year | 16 |
| Share | Attributable | |||||||
| capital and | Capital | to the | Non- | |||||
| share | redemption | Other | Retained | owners of | controlling | Total | ||
| premium | reserve | reserves | earnings | theCompany | interests | equity | ||
| £m | £m | £m | £m | £m | £m | £m | ||
At 1 April 2022 | ||||||||
| Profit for the year – total | ||||||||
operations | ||||||||
| Other comprehensive | ||||||||
| (expense)/income | ( | ( | ( | |||||
| Total comprehensive | ||||||||
(expense)/income | ( | |||||||
| Hedging gains transferred | ||||||||
| to inventory | ( | ( | ( | |||||
Tax effect of the above Transactions with owners: | item | |||||||
Share-based payments, net of | tax | |||||||
| Issue of share capital | ||||||||
| Purchase of own shares | ||||||||
| including net settlement | ||||||||
| (Note 23) | ( | ( | ( | |||||
| Dividends paid (Note 14) | ( | ( | ( | |||||
| Other movements | ||||||||
At 31 March 2023 |
| Share | Attributable | |||||||
| capital and | Capital | to the | Non- | |||||
| share | redemption | Other | Retained | owners of | controlling | Total | ||
| premium | reserve | reserves | earnings | theCompany | interests | equity | ||
| £m | £m | £m | £m | £m | £m | £m | ||
At 31 March 2023 | ||||||||
| Profit for the year – total | ||||||||
| operations | ||||||||
| Other comprehensive | ||||||||
| (expense)/income | ( | ( | ( | |||||
| Total comprehensive | ||||||||
| (expense)/income | ( | |||||||
| Hedging losses transferred | ||||||||
| to inventory | ||||||||
Tax effect of the above Transactions with owners: | item | ( | ( | ( | ||||
Share-based payments, net of Purchase of own shares | tax | |||||||
| including net settlement | ||||||||
| (Note 23) | ( | ( | ( | |||||
| Dividends paid (Note 14) | ( | ( | ( | |||||
| At 31 March 2024 |
| Year ended 31 March 2024 | Year ended 31 March 2023* | ||||||
| Continuing operations | Adjusting | Adjusted | Adjusting | Adjusted | |||
| £m unless otherwise stated | Reported | items | reported | Reported | items | reported | |
Revenue | 1 647 | – | 1 647 | 1 751 | – | 1 751 | |
EBITDA | 301 | 27 | 328 | 291 | 31 | 322 | |
| Depreciation | (58) | 1 | (57) | (59) | 1 | (58) | |
| Amortisation | (36) | 23 | (13) | (36) | 23 | (13) | |
| Operating profit | 207 | 51 | 258 | 196 | 55 | 251 | |
Net finance expense | (6) | – | (6) | (20) | – | (20) | |
| Share of profit/(loss) of joint | venture | 25 | 10 | 35 | (24) | 48 | 24 |
| Profit before tax | 226 | 61 | 287 | 152 | 103 | 255 | |
Income tax expense | (47) | (15) | (62) | (25) | (25) | (50) | |
| Profit for the year | 179 | 46 | 225 | 127 | 78 | 205 | |
Basic earnings per share (pence) | 45.2p | – | – | 31.3p | – | – | |
Diluted earnings per share (pence) | 44.4p | 11.1p | 55.5p | 30.8p | 18.8p | 49.6p | |
| Effective tax rate expense % | 20.6% | 21.6% | 16.8% | 19.9% |
| Year ended 31 March | |||
| 2024 | 2023* | ||
Continuing operations | Notes | £m | £m |
Exceptional costs included in operating profit | 8 | 24 | 28 |
| M&A costs | 27 | 27 | |
Adjusting items excluded from share of profit of joint venture | 22 | 10 | 48 |
| Total excluded from adjusted profit before tax | 61 | 103 | |
Tax credit on adjusting items | 11 | (15) | (25) |
| Total excluded from adjusted profit for the year | 46 | 78 |
| Year ended 31 March | |||
| 2024 | 2023* | ||
Continuing operations | Note | £m | £m |
Amortisation of acquired intangible assets | 19 | 23 | 23 |
| Unwind of fair value adjustments | 2 | 2 | |
| Other M&A activity-related items | 2 | 2 | |
| Total M&A costs | 27 | 27 |
| Year ended 31 March | ||
| 2024 | 2023* | |
| Continuing operations | £m | £m |
Adjusted operating profit from continuing operations | 258 | 251 |
| Adjusted for: | ||
| Adjusted depreciation and adjusted amortisation | 70 | 71 |
| Share-based payments charge | 13 | 20 |
| Other non-cash movements | (4) | (8) |
| Changes in working capital | 7 | (105) |
| Net retirement benefit obligations | (7) | (9) |
| Net capital expenditure | (110) | (71) |
| Net interest and tax paid | (57) | (28) |
| Free cash flow from continuing operations | 170 | 121 |
| Year ended 31 March | |||
| 2024 | 2023* | ||
| Continuing operations | Note | £m | £m |
| Free cash flow from continuing operations | 170 | 121 | |
| Adjusted for: | |||
| Add: free cash flow relating to discontinued operations | – | (7) | |
| Less: exceptional cash flows | 8 | (27) | (59) |
| Less: tax payments relating to Primient and gain on disposal | (24) | (47) | |
| Less: interest received | (19) | (11) | |
| Less: other M&A activity-related items | (2) | (2) | |
| Add: net capital expenditure | 110 | 71 | |
| Net cash generated from operating activities – total operations | 208 | 66 |
| At 31 March | |||
| 2024 | 2023* | ||
Continuing operations | Note | £m | £m |
| Calculation of net debt to EBITDA ratio | |||
Net debt | 28 | 153 | 238 |
| Adjusted operating profit | 258 | 251 | |
| Add back adjusted depreciation and adjusted amortisation | 70 | 71 | |
| EBITDA | 328 | 322 | |
| Net debt to EBITDA ratio (times) | 0.5 | 0.7 |
| At 31 March | ||
| 2024 | 2023* | |
| £m | £m | |
| Calculation ROCE | ||
Adjusted operating profit – continuing operations | 258 | 251 |
| Deduct amortisation on acquired intangible assets and other fair value adjustments | (25) | (25) |
| Profit before interest, tax, other M&A activity-related items and exceptional items for ROCE | 233 | 226 |
| Average invested operating capital | 1 343 | 1 278 |
ROCE % | 17.4% | 17.6% |
| Food & | Primary | Primient | Year ended 31 March 2024 | |||
| Beverage | Products | Joint | ||||
| Solutions | Sucralose | Europe | Venture | Total | ||
| Total operations | £m | £m | £m | £m | £m | |
Revenue | 1 359 | 174 | 114 | – | 1 647 | |
| Adjusted EBITDA | 281 | 52 | (5) | – | 328 | |
| Adjusted EBITDA margin | 20.7% | 29.8% | (4.8%) | – | 19.9% | |
| Adjusted share of profit of joint venture | – | – | – | 35 | 35 | |
Included within statutory operating profit 2 : | ||||||
| – | depreciation | 43 | 11 | 4 | – | 58 |
| – | amortisation | 34 | 2 | – | – | 36 |
| – | share-based payments | 11 | 2 | – | – | 13 |
| Food & | Primary | Primient | Year ended 31 March 2023* | |||
| Beverage | Products | Joint | ||||
| Solutions | Sucralose | Europe | Venture | Total | ||
| Total operations | £m | £m | £m | £m | £m | |
Revenue | 1 438 | 184 | 129 | – | 1 751 | |
| Adjusted EBITDA | 273 | 58 | (9) | – | 322 | |
Adjusted EBITDA margin | 18.9% | 31.3% | (6.5%) | – | 18.4% | |
| Adjusted share of profit of joint venture | – | – | – | 24 | 24 | |
Included within statutory operating profit 2 : | ||||||
| – | depreciation | 47 | 10 | 2 | – | 59 |
| – | amortisation | 34 | 2 | – | – | 36 |
| – | share-based payments | 16 | 3 | 1 | – | 20 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| Total operations | £m | £m |
| Food & Beverage Solutions | ||
| North America | 642 | 687 |
| Asia, Middle East, Africa and Latin America | 396 | 432 |
| Europe | 321 | 319 |
| Food & Beverage Solutions – total | 1 359 | 1 438 |
Sucralose – total | 174 | 184 |
Primary Products Europe | 114 | 129 |
Total | 1 647 | 1 751 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| United Kingdom | 26 | 25 |
| United States | 483 | 517 |
| Other European countries | 301 | 279 |
| Rest of the world | 289 | 318 |
| Non-current assets – total operations | 1 099 | 1 139 |
| Year ended 31 March | |||||||
| 2024 | 2023* | ||||||
| Continuing operations | Notes | £m | £m | ||||
| Revenue | 1 647 | 1 751 | |||||
| Operating expenses | |||||||
| Cost of inventories (included in cost of sales) | 796 | 876 | |||||
| Staff costs (of which £99 million (2023 – £96 million) was included | in | cost | of | sales) | 9 | 262 | 284 |
| Depreciation of property, plant and equipment: | |||||||
| – | owned assets (of which £43 million (2023 – £45 million) was included | ||||||
| in | cost | of | sales) | 49 | 50 | ||
| – | leased assets (of which £1 million (2023 – £1 million) was included | ||||||
| in | cost | of | sales) | 21 | 9 | 9 | |
Exceptional costs | 8 | 24 | 28 | ||||
| Other M&A activity-related items | 4 | 2 | 2 | ||||
| Amortisation of intangible assets: | |||||||
| – | acquired intangible assets | 19 | 23 | 23 | |||
| – | other intangible assets | 19 | 13 | 13 | |||
Impairment of intangible assets | 19 | – | 1 | ||||
Impairment of property, plant and equipment | 20 | 1 | – | ||||
| Total net foreign exchange losses | – | 1 | |||||
| Other operating expenses | 261 | 268 | |||||
| Operating expenses | 1 440 | 1 555 | |||||
| Operating profit | 207 | 196 | |||||
| Year ended 31 March | |||
| 2024 | 2023 | ||
| £m | £m | ||
Fees payable for the audit of the Company and consolidated financial statements | 1.3 | 1.7 | |
| Fees payable for other services: | |||
| – | the audit of the Company’s subsidiaries | 1.8 | 1.7 |
| – | audit-related assurance services | 0.1 | 0.1 |
| Total | 3.2 | 3.5 |
| Year ended 31 March | |||
| 2024 | 2023 | ||
| Continuing operations | Footnotes | £m | £m |
| Income statement | |||
Restructuring costs | (a) | (21) | (5) |
Costs associated with the separation and disposal of Primient | (b) | (4) | (25) |
| Stabiliser product contamination | 1 | (1) | |
| Historical legal matters | – | 3 | |
| Exceptional items included in operating profit | (24) | (28) | |
| Exceptional items related to share of profit of joint venture (see Note 22) | (1) | (52) | |
| Exceptional items included in profit before tax | (25) | (80) | |
| Exceptional items – continuing operations | (25) | (80) |
| Year ended 31 March | |||
| 2024 | 2023 | ||
| Discontinued operations | Note | £m | £m |
Gain on disposal of Primient | 12 | – | 98 |
| Exceptional items – discontinued operations | – | 98 | |
| Exceptional items – total operations | (25) | 18 |
| Year ended 31 March | |||
| 2024 | 2023 | ||
Net operating cash (outflows)/inflows on exceptional items | Footnotes | £m | £m |
Restructuring costs | (a) | (18) | (3) |
Costs associated with the separation and disposal of Primient | (b) | (7) | (52) |
US pension plan past service credit | (c) | (1) | (1) |
| Stabiliser product contamination | 1 | (1) | |
| Historical legal matters | (2) | (2) | |
| Net cash outflows – continuing operations | (27) | (59) | |
| Net cash outflows – discontinued operations | (12) | (42) | |
| Net cash outflows – total operations | (39) | (101) |
| Year ended 31 March | |||
| 2024 | 2023 | ||
| Continuing operations | £m | £m | |
| Wages and salaries | 220 | 229 | |
| Social security costs | 27 | 31 | |
| Retirement benefit costs: | |||
| – | defined contribution schemes | 13 | 10 |
| Share-based payments | 13 | 20 | |
| Staff costs – continuing operations | 273 | 290 |
| Year ended 31 March | ||
By operating segment | 2024 | 2023 |
| Food & Beverage Solutions | 3 316 | 3 455 |
Sucralose 1 | 115 | 117 |
Primary Products Europe 2 | – | – |
| Total | 3 431 | 3 572 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| Salaries and short-term employee benefits | 7 | 11 |
| Retirement benefits | 1 | 1 |
| Share-based payments | 7 | 10 |
| Total | 15 | 22 |
| Year ended 31 March | |||
| 2024 | 2023 | ||
Continuing operations | Notes | £m | £m |
| Interest payable on bank and other borrowings | (20) | (27) | |
Lease interest | 21 | (2) | (2) |
Net retirement benefit interest | 31 | (3) | (3) |
| Finance expense | (25) | (32) | |
| Finance income – income on cash balances | 19 | 12 | |
| Net finance expense | (6) | (20) |
| Year ended 31 March | ||
| 2024 | 2023 | |
| Continuing operations | £m | £m |
| Current tax | ||
| United Kingdom | (5) | (1) |
| Overseas | (76) | (66) |
| Tax credit on exceptional items | 8 | 6 |
| Credit in respect of previous financial years | 2 | 16 |
| (71) | (45) | |
| Deferred tax | ||
| Credit for the year | 21 | 13 |
| Credit/(charge) in respect of previous financial years | 4 | (6) |
| Tax charge on exceptional items | (1) | – |
| Tax credit on Primient exceptional items | – | 13 |
| Income tax expense | (47) | (25) |
| Statutory effective tax rate (%) | 20.6% | 16.8% |
| Year ended 31 March | ||||
| 2024 | 2023* | |||
| Continuing operations | Note | £m | £m | |
| Income tax expense | (47) | (25) | ||
| Add back the impact of: | ||||
| Tax credit on exceptional items | (7) | (6) | ||
| Tax credit on Primient exceptional items | – | (13) | ||
| Tax credit on amortisation of acquired intangibles and other fair value | ||||
| adjustments | (6) | (7) | ||
Tax (credit)/charge on amortisation of Primient acquired intangibles and other fair value | adjustments | (2) | 1 | |
Adjusted income tax expense | 4 | (62) | (50) | |
| Adjusted effective tax rate (%) | 21.6% | 19.9% |
| Year ended 31 March | |||
| 2024 | 2023 | ||
| Continuing operations | £m | £m | |
| Profit before tax | 226 | 152 | |
| Corporation tax charge thereon at 25% (2023 – 19%) | (57) | (29) | |
| Adjusted for the effects of: | |||
| – | non-deductible income and other permanent items | (8) | (14) |
| – | adjustments in respect of previous financial year | 6 | 10 |
| – | losses and tax credits now treated as being recoverable in future periods | 7 | 10 |
| – | changes in tax rates | – | 1 |
| – | tax rates below/(above) the UK rate applied on overseas earnings | 5 | (3) |
| Total tax charge | (47) | (25) |
| Year ended 31 March 2024 | Year ended 31 March 2023* | |||||
| Tax credit/ | ||||||
| Pre-tax | Tax credit | Pre-tax | (charge) | |||
Continuing operations | Notes | £m | £m | £m | £m | |
| Exceptional items | ||||||
Restructuring costs | 8 | (21) | 5 | (5) | 1 | |
| Costs associated with the separation and disposal | ||||||
of Primient | 8 | (4) | 2 | (25) | 6 | |
Stabiliser product contamination | 8 | 1 | – | (1) | – | |
Historical legal matters | 8 | – | – | 3 | (1) | |
| Exceptional items included in profit before tax | (24) | 7 | (28) | 6 | ||
Group share of exceptional items recognised by joint venture | 22 | (1) | – | (52) | 13 | |
Amortisation of acquired intangible assets and other fair value adjustments | (25) | 6 | (25) | 7 | ||
| Other M&A activity-related items | (2) | – | (2) | – | ||
| Amortisation of Primient acquired intangibles | ||||||
| and | other fair value adjustments | 22 | (9) | 2 | 4 | (1) |
Total adjusting items – continuing operations | 4 | (61) | 15 | (103) | 25 | |
| Discontinued operations | ||||||
Gain on disposal of Primient | 8, 12 | – | 9 | 98 | (33) | |
| Exceptional items – discontinued operations | – | 9 | 98 | (33) | ||
| Total adjusting items – total operations | (61) | 24 | (5) | (8) |
| Capital | ||||||||||
| allowances | Retirement | Share- | ||||||||
| in excess of | benefit | based | Tax | |||||||
| Investments | depreciation | obligations | payments | losses | Other | Total | ||||
| £m | £m | £m | £m | £m | £m | £m | ||||
At 1 April 2022 | – | (73) | 24 | 4 | 22 | (19) | (42) | |||
| Credited/(charged) to the | income | statement | ||||||||
| – | underlying | 22 | (3) | (1) | 2 | (10) | 6 | 16 | ||
| – | exceptional items – | |||||||||
| Disposal of Primient | (78) | 63 | (5) | – | – | 48 | 28 | |||
| – | Credited to other | |||||||||
| comprehensive income | 6 | – | – | – | – | – | 6 | |||
Credited directly to equity | – | – | – | 1 | – | 5 | 6 | |||
Acquisition of businesses | – | – | – | – | – | (24) | (24) | |||
| Currency translation | differences | – | (8) | 1 | – | 3 | (3) | (7) | ||
At 31 March 2023 | (50) | (21) | 19 | 7 | 15 | 13 | (17) | |||
| Credited/(charged) to the | income | statement | ||||||||
| – | underlying | 9 | 4 | – | 2 | 2 | 8 | 25 | ||
| – | exceptional items | (1) | – | – | – | – | – | (1) | ||
| – | exceptional items – | |||||||||
| (Charged)/credited to | Disposal of Primient | 6 | – | – | – | – | – | 6 | ||
| other comprehensive | ||||||||||
| income | (1) | – | (4) | – | – | 1 | (4) | |||
| Credited directly to equity | – | – | – | (1) | – | (1) | (2) | |||
| Currency translation | differences | 2 | 1 | (1) | (1) | – | 1 | 2 | ||
| At 31 March 2024 | (35) | (16) | 14 | 7 | 17 | 22 | 9 | |||
| Year ended 31 March | ||
| Discontinued operations | 2024 | 2023* |
| £ million unless otherwise stated | £m | £m |
Revenue | – | – |
Operating income | – | 96 |
Operating profit | – | 96 |
Finance expense | – | – |
| Share of profit after tax of joint venture | – | – |
| Profit before tax | – | 96 |
Income tax credit/(expense) | 9 | (33) |
| Profit for the year from discontinued operations | 9 | 63 |
Basic earnings per share from discontinued operations (pence) | 2.1p | 15.7p |
Diluted earnings per share from discontinued operations (pence) | 2.1p | 15.4p |
| Year ended 31 March | ||
| 2024 | 2023 | |
| Discontinued operations | £m | £m |
| Operating | (12) | (49) |
| Investing | 12 | 1 045 |
| Net cash inflow | – | 996 |
Year ended 31 March 2024 | Year ended 31 March 2023 | |||||
| Discontinued operations | Adjusting | Adjusted | Adjusting | Adjusted | ||
| £ million unless otherwise stated | Reported | items | reported | Reported | items | reported |
Revenue | – | – | – | – | – | – |
EBITDA | – | – | – | 96 | (98) | (2) |
Depreciation | – | – | – | – | – | – |
| Amortisation | – | – | – | – | – | – |
| Operating profit/(loss) | – | – | – | 96 | (98) | (2) |
Finance expense | – | – | – | – | – | – |
| Share of profit after tax of joint venture | – | – | – | – | – | – |
| Profit/(loss) before tax | – | – | – | 96 | (98) | (2) |
Income tax credit/(expense) | 9 | (9) | – | (33) | 33 | – |
| Profit/(loss) for the year | 9 | (9) | – | 63 | (65) | (2) |
Basic earnings per share (pence) | 2.1p | – | – | 15.7p | (16.1p) | (0.4p) |
Diluted earnings per share (pence) | 2.1p | – | – | 15.4p | (15.8p) | (0.4p) |
Effective tax rate % | n/a | – | 34.0% | 25.4% |
| Year ended 31 March | ||
| 2024 | 2023 | |
| Discontinued operations | £m | £m |
| Exceptional income in operating profit | – | (98) |
| Total excluded from adjusted operating profit | – | (98) |
| Total excluded from adjusted profit before tax | – | (98) |
| Tax effect of adjusting items | – | 33 |
| Exceptional tax credit | (9) | – |
| Total excluded from adjusted profit for the year | (9) | (65) |
| Year ended | |||
| 31 March | |||
| 2023 | |||
| £m | |||
Adjusted operating profit from discontinued | operations | (2) | |
| Adjusted for: | |||
Changes in working capital and other non-cash movements | (5) | ||
| Net interest and tax paid | – | ||
| Free cash flow from discontinued | operations | (7) |
| Year ended 31 March | ||
| 2023 | 2023 | |
| Gross cash received (in US dollars and pound sterling) | US$m | £m |
Cash consideration – as shown in gain on disposal table below | 330 | 253 |
Less: completion accounts adjustments in favour of the Group not yet received | (15) | (12) |
| Add: cash received for intercompany loan notes, payables and transaction costs | 1 089 | 830 |
| Add: contingent consideration received | 31 | 24 |
| Disposal of Primient, gross proceeds | 1 435 | 1 095 |
| Year ended | |||
| 31 March | |||
| 2023 | |||
Gain on disposal | Notes | £m | |
| Cash consideration – as shown in table opposite | 253 | ||
| Contingent consideration received | 24 | ||
Fair value of investment in Primient joint venture on initial recognition | 22 | 253 | |
| Total consideration for equity | 530 | ||
| Primient net assets derecognised on disposal on 1 April | (539) | ||
Recycling of accumulated foreign exchange from other comprehensive income to the income | statement | 81 | |
| Recycling of cash flow hedges from other comprehensive income to the income statement | 48 | ||
| Impact of deal contingent forward | (33) | ||
| Other amounts | 11 | ||
Gain on disposal before tax | 8 | 98 | |
| Tax on gain on disposal | (33) | ||
| Gain on disposal | 65 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| Cash flows | £m | £m |
| Total cash consideration of £253 million less completion accounts adjustment | ||
| not yet received of £12 million – as shown above | – | 241 |
Completion accounts adjustment received | 12 | – |
| Repayment of intercompany loan notes and payables and transaction costs | – | 830 |
| Less: cash outflow relating to deal contingent forward | – | (33) |
| Less: net cash derecognised on disposal | – | (17) |
| Add: contingent consideration received – as shown above | – | 24 |
| Disposal of business, net of cash derecognised on disposal | 12 | 1 045 |
Year ended 31 March 2024 | Year ended 31 March 2023 | ||||||
| Continuing | Discontinued | Total | Continuing | Discontinued | Total | ||
| Profit attributable to owners of the | operations | operations | operations | operations | operations | operations | |
| Company (£ | million) | 179 | 9 | 188 | 127 | 63 | 190 |
| Weighted average number | |||||||
| of | ordinary shares (million) | ||||||
| – | basic | 397.1 | 397.1 | 397.1 | 404.1 | 404.1 | 404.1 |
| Basic earnings per share (pence) | 45.2p | 2.1p | 47.3p | 31.3p | 15.7p | 47.0p | |
| Weighted average number | |||||||
| of | ordinary shares (million) | ||||||
| – | diluted | 404.2 | 404.2 | 404.2 | 411.4 | 411.4 | 411.4 |
| Diluted earnings per share (pence) | 44.4p | 2.1p | 46.5p | 30.8p | 15.4p | 46.2p | |
| Year ended 31 March | ||||
| 2024 | 2023 | |||
| Calculation of weighted average number of ordinary shares | Million | Million | ||
Weighted average number of ordinary shares – basic | 397.1 | 404.1 | ||
| Effects of dilution from: | ||||
| – | Sharesave plan | 0.1 | 0.1 | |
| – | Performance share plan/Restricted share awards/Group Bonus plan – deferred | element | 7.0 | 7.2 |
| Weighted average number of ordinary shares – diluted | 404.2 | 411.4 |
| Year ended 31 March | ||||
| 2024 | 2023* | |||
| Continuing operations | Notes | £m | £m | |
| Profit attributable to owners of the Company | 179 | 127 | ||
| Adjusting items: | ||||
| – | exceptional costs in operating profit | 8 | 24 | 28 |
| – | M&A costs | 4 | 27 | 27 |
| – | adjusting items excluded from share of profit of joint venture | 22 | 10 | 48 |
| – | tax credit on adjusting items | 11 | (15) | (25) |
Adjusted profit attributable to owners of the Company | 4 | 225 | 205 | |
| Weighted average number of ordinary shares (million) – diluted | 404.2 | 411.4 | ||
| Adjusted earnings per share (pence) – continuing operations | 55.5p | 49.6p |
| Year ended 31 March | ||||
| 2024 | 2023* | |||
| Total operations | Notes | £m | £m | |
Adjusted profit attributable to owners of the Company – continuing operations | 4 | 225 | 205 | |
| Adjusted loss attributable to owners of the Company – discontinued | operations | 12 | – | (2) |
| Adjusted profit attributable to owners of the Company – total | operations | 225 | 203 | |
| Adjusted earnings per share (pence) – total operations | 55.5p | 49.2p |
| Year ended 31 March | |||
| 2024 | 2023 | ||
| Pence | Pence | ||
| Per ordinary share: | |||
| – | interim dividend paid | 6.2 | 5.4 |
| – | final dividend proposed | ||
| Total dividend | 19.1 | 18.5 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
Final dividend paid relating to the prior financial year | 52 | 51 |
| Interim dividend paid relating to the financial year | 24 | 22 |
| Total dividend paid relating to prior and current financial year | 76 | 73 |
Special dividend | – | 497 |
| Total dividend paid | 76 | 570 |
| 2024 | 2023 | |
| £m | £m | |
Raw materials and consumables | 106 | 130 |
Work in progress | 20 | 38 |
| Finished goods | 227 | 278 |
| Total | 353 | 446 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
Short-term highly liquid investments | 330 | 392 |
Cash at bank | 107 | 83 |
| Cash and cash equivalents | 437 | 475 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
US dollar | 363 | 404 |
Euro | 4 | 6 |
| Sterling | 14 | 18 |
| Other | 56 | 47 |
| Total | 437 | 475 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| Trade receivables | 240 | 290 |
| Less loss allowance provision | (7) | (12) |
| Trade receivables – net | 233 | 278 |
| Prepayments and accrued income | 16 | 16 |
| Other receivables | 45 | 57 |
| Total | 294 | 351 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| US dollar | 176 | 190 |
| Euro | 68 | 104 |
| Sterling | 8 | 11 |
| Other | 53 | 57 |
| Total | 305 | 362 |
| Greater | At 31 March 2024 | ||||
| 30 – 60 | 60 – 90 | than 90 | |||
| days | days | days | |||
£ million unless otherwise stated | Current | past due | past due | past due | Total |
| Expected loss rate % | 1% | 46% | – | 84% | |
| Gross carrying amount | 233 | 2 | – | 5 | 240 |
| Loss allowance provision | 2 | 1 | – | 4 | 7 |
| At 31 March 2023 | |||||
Expected loss rate % | 1% | 1% | 19% | 100% | |
Gross carrying amount | 262 | 16 | 2 | 10 | 290 |
Loss allowance provision | 2 | – | – | 10 | 12 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| At 1 April | 12 | 12 |
Utilisation of provision | (7) | – |
Change in loss allowance recognised in the income statement | 2 | – |
| At 31 March | 7 | 12 |
| Financial | Financial | Total | ||
| assets | assets | investments | ||
| at FVPL | at FVOCI | in equities | ||
| £m | £m | £m | ||
At 1 April 2023 | 20 | 22 | 42 | |
| Total gains/(losses) | ||||
| – | in operating profit | – | – | – |
| – | in other comprehensive income | – | (17) | (17) |
| Re-measurement of non-qualified deferred compensation arrangements | 3 | – | 3 | |
| Purchases | 2 | 1 | 3 | |
| Disposals | (3) | – | (3) | |
| At 31 March 2024 | 22 | 6 | 28 | |
At 1 April 2022 | 20 | 26 | 46 | |
| Total gains/(losses) | ||||
| – | in operating profit | – | – | – |
| – | in other comprehensive income | – | 3 | 3 |
Re-measurement of non-qualified deferred compensation arrangements | (2) | – | (2) | |
Purchases | 3 | – | 3 | |
Disposals | (3) | (7) | (10) | |
Currency translation differences | 2 | – | 2 | |
At 31 March 2023 | 20 | 22 | 42 | |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
US dollar | 26 | 40 |
Sterling | 1 | 2 |
| Euro | 1 | – |
| Total | 28 | 42 |
| Other | Product | |||||
| acquired | Computer | development | Assets under | |||
| Goodwill | intangibles | software | costs | construction | Total | |
| £m | £m | £m | £m | £m | £m | |
| Cost | ||||||
At 1 April 2023 | 318 | 310 | 59 | 143 | 14 | 844 |
| Additions at cost | – | – | – | 2 | 7 | 9 |
| Disposals and write-offs | – | – | (1) | – | – | (1) |
| Transfers on completion | – | 1 | – | 4 | (5) | – |
| Currency translation differences | (12) | (12) | (1) | (4) | – | (29) |
| At 31 March 2024 | 306 | 299 | 57 | 145 | 16 | 823 |
Accumulated amortisation and impairment | ||||||
At 1 April 2023 | 10 | 213 | 47 | 122 | – | 392 |
| Impairment charge | – | – | – | – | – | – |
| Amortisation charge | – | 23 | 6 | 7 | – | 36 |
| Disposals and write-offs | – | – | (1) | – | – | (1) |
| Currency translation differences | – | (6) | (1) | (3) | – | (10) |
| At 31 March 2024 | 10 | 230 | 51 | 126 | – | 417 |
Net book value at 31 March 2024 | 296 | 69 | 6 | 19 | 16 | 406 |
| Other | Product | ||||||
| acquired | Computer | development | Assets under | ||||
| Goodwill | intangibles | software | costs | construction | Total | ||
| £m | £m | £m | £m | £m | £m | ||
| Cost | |||||||
At 1 April 2022 | 213 | 216 | 53 | 127 | 22 | 631 | |
Additions at cost | – | – | – | 3 | 5 | 8 | |
Subsidiary acquired | 96 | 96 | – | – | – | 192 | |
Disposals and write-offs | – | (10) | – | – | (2) | (12) | |
Transfers on completion | – | 1 | 4 | 7 | (12) | – | |
Currency translation differences | 9 | 7 | 2 | 6 | 1 | 25 | |
At 31 March 2023 | 318 | 310 | 59 | 143 | 14 | 844 | |
| Accumulated amortisation | |||||||
and At 1 April 2022 | impairment | 10 | 192 | 41 | 110 | – | 353 |
Impairment charge | – | – | – | – | 1 | 1 | |
Amortisation charge | – | 23 | 6 | 7 | – | 36 | |
Disposals and write-offs | – | (10) | – | – | (1) | (11) | |
Currency translation differences | – | 8 | – | 5 | – | 13 | |
At 31 March 2023 | 10 | 213 | 47 | 122 | – | 392 | |
Net book value at 31 March 2023 | 308 | 97 | 12 | 21 | 14 | 452 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| Allocated by operating segment | ||
Food & Beverage Solutions | 208 | 213 |
| Goodwill allocated to operating segments | 208 | 213 |
Goodwill allocated to Quantum Hi-Tech (Guangdong) Biological Co., Ltd | 88 | 95 |
Goodwill – total operations | 296 | 308 |
| Assets in the | ||||
| Land and | Plant and | course of | ||
| buildings | machinery | construction | Total | |
| £m | £m | £m | £m | |
Cost | 321 | 1 074 | 89 | 1 484 |
| At 1 April 2023 | ||||
| Additions at cost | 4 | 6 | 104 | 114 |
| Transfers on completion | 7 | 43 | (50) | – |
| Disposals and write-offs | (7) | (6) | (1) | (14) |
| Currency translation differences and other movements | (9) | (31) | (3) | (43) |
| At 31 March 2024 | 316 | 1 086 | 139 | 1 541 |
| Accumulated depreciation and impairment | ||||
At 1 April 2023 | 158 | 838 | – | 996 |
| Depreciation charge | 16 | 42 | – | 58 |
| Impairment charge | – | – | 1 | 1 |
| Disposals and write-offs | (7) | (6) | (1) | (14) |
| Currency translation differences and other movements | (5) | (23) | – | (28) |
| At 31 March 2024 | 162 | 851 | – | 1 013 |
Net book value at 31 March 2024 | 154 | 235 | 139 | 528 |
| Cost | ||||
At 1 April 2022 | 285 | 979 | 64 | 1 328 |
Additions at cost | 6 | 4 | 70 | 80 |
Subsidiary acquired | 12 | 7 | 1 | 20 |
Transfers on completion | 7 | 40 | (47) | – |
Disposals and write-offs | (2) | (8) | – | (10) |
Currency translation differences and other movements | 13 | 52 | 1 | 66 |
At 31 March 2023 | 321 | 1 074 | 89 | 1 484 |
| Accumulated depreciation and impairment | ||||
At 1 April 2022 | 138 | 759 | – | 897 |
Depreciation charge | 15 | 44 | – | 59 |
Impairment charge | – | – | – | – |
Disposals and write-offs | (2) | (8) | – | (10) |
Currency translation differences and other movements | 7 | 43 | – | 50 |
At 31 March 2023 | 158 | 838 | – | 996 |
Net book value at 31 March 2023 | 163 | 236 | 89 | 488 |
| Land and | Plant and | ||
| buildings | machinery | Total | |
| £m | £m | £m | |
| Right-of-use assets | |||
At 1 April 2022 | 36 | 4 | 40 |
Additions to right-of-use assets | 4 | 2 | 6 |
Depreciation charge | (7) | (2) | (9) |
Impairment | – | – | – |
Currency translation differences | 2 | – | 2 |
At 31 March 2023 | 35 | 4 | 39 |
Additions to right-of-use assets | 3 | 2 | 5 |
Depreciation charge | (6) | (3) | (9) |
| Impairment | – | – | – |
| Currency translation differences | – | (1) | (1) |
| At 31 March 2024 | 32 | 2 | 34 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
Depreciation expense of right-of-use assets | 9 | 9 |
Interest expense on lease liabilities | 2 | 2 |
| Expense relating to short-term leases | – | – |
| Expense relating to leases of low-value assets | – | – |
| Expense relating to variable lease payments not included in the measurement of lease liability | – | – |
| Income from sub-leasing right-of-use assets | – | 2 |
11 | 13 |
| Year ended 31 March | |||
| Primient | Primient | ||
| 2024 | 2023 | ||
| Note | £m | £m | |
| At 1 April | 199 | – | |
| Fair value of investment in joint venture on initial recognition | – | 253 | |
| Share of profit/(loss) profit of joint venture | 25 | (24) | |
Other comprehensive income/(expense) (including foreign exchange) | 24 | 2 | (5) |
| Dividends paid | (59) | (41) | |
| Other movements (including contributions) | (2) | 17 | |
| Share redemption | – | (1) | |
| At 31 March | 165 | 199 |
| Year ended | Year ended | |
| 31 March | 31 March | |
| 2024 | 2023 | |
| Primient | £m | £m |
| At 100% | ||
| Revenue | 2 249 | 2 552 |
| Depreciation and amortisation | (104) | (85) |
| Other expenses | (1 970) | (2 329) |
| Exceptional items | (2) | (61) |
| Net finance expense | (92) | (80) |
| Profit/(loss) before tax | 81 | (3) |
Income tax expense 1 | (12) | (6) |
| Profit/(loss) after tax at 100% | 69 | (9) |
| Other comprehensive expense at 100% | (1) | (41) |
| Total comprehensive income/(expense) at 100% | 68 | (50) |
| At 49.7% | ||
| Group’s share of profit/(loss) for the year | 34 | (4) |
| Amortisation of fair value adjustments on initial recognition of Primient | (9) | (17) |
| Other Group adjustments | – | (3) |
| Group’s share of profit/(loss) of joint venture | 25 | (24) |
| Group’s share of other comprehensive expense | – | (21) |
| Group adjustments to other comprehensive income | 2 | 16 |
| Group’s share of other comprehensive income/(expense) | 2 | (5) |
| Group’s share of total comprehensive income/(expense) | 27 | (29) |
| At 31 March | At 31 March | |
| 2024 | 2023 | |
| Primient | £m | £m |
| Assets | ||
| Non-current assets | 1 022 | 993 |
| Cash and cash equivalents | 26 | 43 |
| Other current assets | 496 | 624 |
| Liabilities | ||
| Non-current liabilities | (1 011) | (1 072) |
| Current borrowings | (27) | (9) |
| Other current liabilities | (277) | (303) |
| Net assets at 100% | 229 | 276 |
| Group share of net assets | 114 | 137 |
| Goodwill and fair value adjustments (net of amortisation) | 51 | 62 |
| Carrying amount of investment in Primient | 165 | 199 |
| Year ended 31 March 2024 | |||
| Primient income statement at Group’s share | Adjusting | Adjusted | |
| £m | Reported | items | reported |
Revenue | 1 118 | – | 1 118 |
Operating profit | 61 | 10 | 71 |
Profit before tax | 31 | 10 | 41 |
Income tax expense | (6) | – | (6) |
| Profit after tax | 25 | 10 | 35 |
| Year ended 31 March 2023 | |||
| Primient income statement at Group’s share | Adjusting | Adjusted | |
| £m | Reported | items | reported |
Revenue | 1 267 | – | 1 267 |
Operating profit | 1 | 48 | 49 |
(Loss)/profit before tax | (21) | 48 | 27 |
Income tax expense | (3) | – | (3) |
(Loss)/profit after tax | (24) | 48 | 24 |
| Year ended | Year ended | ||
| 31 March | 31 March | ||
| 2024 | 2023 | ||
Primient’s adjusting items at Group’s share | Note | £m | £m |
| Exceptional costs included in operating profit | 1 | 52 | |
| Amortisation of acquired intangible assets and other fair value adjustments | 9 | (4) | |
Total excluded from adjusted share of profit | 4 | 10 | 48 |
| Ordinary | Share | ||
| share capital | premium | Total | |
| £m | £m | £m | |
At 1 April 2022 | 117 | 407 | 524 |
Allotted under share option schemes | – | 1 | 1 |
| At 31 March 2023 | 117 | 408 | 525 |
Allotted under share option schemes | – | – | – |
| At 31 March 2024 | 117 | 408 | 525 |
Year ended 31 March 2024 | Year ended 31 March 2023 | |||
| Number of | Cost | Number of | Cost | |
| shares | £m | shares* | £m | |
At 1 April | 401 637 112 | 117 | 468 534 065 | 117 |
Impact of share consolidation | – | – | (66 933 968) | – |
| Allotted under share option schemes | 57 349 | – | 37 015 | – |
| At 31 March | 401 694 461 | 117 | 401 637 112 | 117 |
Year ended 31 March 2024 | Year ended 31 March 2023 | ||||
| Number of | Cost | Number of | Cost | ||
| shares | £m | shares | £m | ||
At 1 April | 3 965 498 | 32 | 4 066 931 | 30 | |
Impact of share consolidation | – | – | (576 479) | – | |
Purchased in the market 1 : | |||||
| – | into the EBT | 2 800 000 | 20 | 1 300 000 | 9 |
| Transferred to employees: | |||||
| – | from the EBT | (1 206 503) | (11) | (824 954) | (7) |
| At 31 March | 5 558 995 | 41 | 3 965 498 | 32 | |
At 31 March 2024 | At 31 March 2023 | |||||
| Market | % of | Market | % of | |||
| Number of | value | outstanding | Number of | value | outstanding | |
| shares | £m | share capital | shares | £m | share capital | |
Shares held in the EBT | 5 558 995 | 34 | 1.4% | 3 965 498 | 32 | 1% |
Total | 5 558 995 | 34 | 1.4% | 3 965 498 | 32 | 1% |
| Cost of | Currency | |||||||||||
| Hedging | hedging | FVOCI | translation | Pre-IFRS | ||||||||
| reserve | reserve | reserve | reserve | reserves | Total | |||||||
| £m | £m | £m | £m | £m | £m | |||||||
At 1 April 2022 | 50 | (5) | – | 73 | 104 | 222 | ||||||
| Cash flow hedges: | ||||||||||||
| – | fair value losses in the year | (2) | – | – | – | – | (2) | |||||
| – | hedging gain transferred | |||||||||||
| to inventory | (19) | – | – | – | – | (19) | ||||||
| – | fair value gain on cash flow hedges | |||||||||||
| transferred to income statement on | sale | |||||||||||
| of a subsidiary | (48) | – | – | – | – | (48) | ||||||
| – | cost of hedging transferred to | |||||||||||
| income | statement | – | 5 | – | – | – | 5 | |||||
| – | tax effect of the above items | 5 | – | – | – | – | 5 | |||||
| FVOCI financial assets: | ||||||||||||
| – | fair value gain in the year | – | – | 3 | – | – | 3 | |||||
| Currency translation differences: | ||||||||||||
| – | gain on currency translation | |||||||||||
| of | foreign | operations | – | – | – | 62 | – | 62 | ||||
| – | fair value loss on net investment | hedges | – | – | – | (33) | – | (33) | ||||
| – | fair value loss on net investment hedges | |||||||||||
| statement | transferred to income | – | – | – | 28 | – | 28 | |||||
| – | gain on currency translation of | |||||||||||
| operations transferred to | foreign | income | ||||||||||
| a | statement on sale of | subsidiary | – | – | – | (81) | – | (81) | ||||
| Share of other comprehensive | (expense)/income | of joint venture | (24) | – | – | 19 | – | (5) | ||||
| Tax effect on the above item | 6 | – | – | – | – | 6 | ||||||
At 31 March 2023 | (32) | – | 3 | 68 | 104 | 143 | ||||||
| Cash flow hedges: | ||||||||||||
| – | fair value losses in the year | (6) | – | – | – | – | (6) | |||||
| – | hedging losses transferred | |||||||||||
| to inventory | 4 | – | – | – | – | 4 | ||||||
| – | tax effect of the above items | (1) | – | – | – | – | (1) | |||||
| FVOCI financial assets: | ||||||||||||
| – | fair value loss in the year | – | – | (17) | – | – | (17) | |||||
| Currency translation differences: | ||||||||||||
| – | loss on currency translation | |||||||||||
| operations | foreign | of | – | – | – | (50) | – | (50) | ||||
| – | fair value gain on net investment | hedges | – | – | – | 7 | – | 7 | ||||
| Share of other comprehensive | (expense)/income | of joint venture | (1) | – | – | 3 | – | 2 | ||||
| At 31 March 2024 | (36) | – | (14) | 28 | 104 | 82 | ||||||
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| Current trade and other payables | ||
| Trade payables | 174 | 250 |
| Social security | 3 | 7 |
| Accruals and deferred income | 64 | 99 |
| Other payables | 18 | 16 |
| Total | 259 | 372 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| US dollar | 128 | 220 |
| Euro | 74 | 86 |
| Sterling | 18 | 28 |
| Other | 39 | 38 |
| Total | 259 | 372 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
US Private Placement Notes 2025 – 2032 1 | 537 | 548 |
Total loan notes | 537 | 548 |
Lease liabilities | 36 | 44 |
| Total non-current borrowings | 573 | 592 |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
Short-term loans and facilities | 7 | 14 |
US Private Placement Notes 2023 | – | 97 |
| Lease liabilities | 10 | 10 |
| Total current borrowings | 17 | 121 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
US$95m US Private Placement FRN 1 2023 | – | 6.4% |
US$25m 3.83% US Private Placement Notes 2023 | – | 3.8% |
| US$180m 4.06% US Private Placement Notes 2025 | 4.1% | 4.1% |
| US$100m 4.16% US Private Placement Notes 2027 | 4.2% | 4.2% |
| US$100m 3.31% US Private Placement Notes 2029 | 3.3% | 3.3% |
| US$100m 2.91% US Private Placement Notes 2030 | 2.9% | 2.9% |
| US$100m 3.41% US Private Placement Notes 2031 | 3.4% | 3.4% |
| US$100m 3.01% US Private Placement Notes 2032 | 3.0% | 3.0% |
| Lease liabilities | 3.9% | 3.4% |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
Decrease/(increase) in inventories | 78 | (118) |
Decrease/(increase) in receivables | 36 | (55) |
| (Decrease)/increase in payables | (103) | 71 |
| Movement in derivative financial instruments (excluding debt-related derivatives) | – | (6) |
| Decrease in provisions for other liabilities and charges | (4) | (2) |
| Change in working capital | 7 | (110) |
Other non-cash movements | (3) | (7) |
Change in working capital and other non-cash movements | 4 | (117) |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
Net debt at beginning of the year | (238) | (626) |
Net (decrease)/increase in cash and cash equivalents | (27) | 303 |
Net decrease in borrowings and lease liabilities | 114 | 15 |
| Decrease in net debt resulting from cash flows | 87 | 318 |
Currency translation differences | 2 | 3 |
| Lease liabilities | (7) | 69 |
| Other non-cash movements | 3 | (2) |
| Decrease in net debt in the year | 85 | 388 |
Net debt at end of the year | (153) | (238) |
| Cash and | Borrowings | ||
| cash | and lease | ||
| equivalents | liabilities | Total | |
| £m | £m | £m | |
At 1 April 2022 | 127 | (753) | (626) |
Movement from cash flows | 303 | 15 | 318 |
Currency translation differences | 45 | (42) | 3 |
Lease liabilities | – | 69 | 69 |
Other non-cash movements | – | (2) | (2) |
At 31 March 2023 | 475 | (713) | (238) |
Movement from cash flows | (27) | 114 | 87 |
Currency translation differences | (11) | 13 | 2 |
| Lease liabilities | – | (7) | (7) |
| Other non-cash movements | – | 3 | 3 |
| At 31 March 2024 | 437 | (590) | (153) |
| At 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
US dollar | (204) | (279) |
Euro | 1 | 3 |
| Sterling | 4 | 5 |
| Other | 46 | 33 |
| Total | (153) | (238) |
| Derivatives | At 31 March 2024 | ||||||
| Amortised | in a hedging | Investments | Total | ||||
| cost/cash | relationship | in equities | carrying value | Fair value | |||
| Notes | £m | £m | £m | £m | £m | ||
Investments in equities | 18 | – | – | 28 | 28 | 28 | |
Trade and other receivables | 17 | 279 | – | – | 279 | 279 | |
| Cash and cash equivalents | 16 | 437 | – | – | 437 | 437 | |
| Trade and other payables | 25 | (256) | – | – | (256) | (256) | |
| Borrowings | 26 | (590) | – | – | (590) | (539) | |
| Commodity derivative net | liability | – | (3) | – | (3) | (3) |
| Derivatives | At 31 March 2023 | ||||||
| Amortised | in a hedging | Investments | Total | ||||
| cost/cash | relationship | in equities | carrying value | Fair value | |||
| Notes | £m | £m | £m | £m | £m | ||
Investments in equities | 18 | – | – | 42 | 42 | 42 | |
Trade and other receivables | 17 | 336 | – | – | 336 | 336 | |
Cash and cash equivalents | 16 | 475 | – | – | 475 | 475 | |
Trade and other payables | 25 | (365) | – | – | (365) | (365) | |
Borrowings | 26 | (713) | – | – | (713) | (662) | |
| Commodity derivative net | liability | – | (1) | – | (1) | (1) |
At 31 March 2024 | At 31 March 2023 | |||
| Assets | Liabilities | Assets | Liabilities | |
| £m | £m | £m | £m | |
Non-current derivative financial instruments | – | – | – | – |
Current derivative financial instruments | – | (3) | 3 | (4) |
– | (3) | 3 | (4) |
| At 31 March | |||
| 2024 | 2023 | ||
| Borrowings used to net investment hedge currency translation risk | £m | £m | |
Notional principal amounts of borrowings (weighted liability) | 320 | 552 | |
| Gain/(loss) on translation of borrowings recognised in currency | |||
| translation | reserve | 7 | (33) |
| Carrying amount of hedging instrument | 320 | 552 | |
| Maturity date | Oct 2025-Aug 2032 | Oct 2023-Aug 2032 | |
| Hedge ratio | 1:1 | 1:1 | |
Change in intrinsic value of outstanding hedging instruments used to determine hedge effectiveness | 7 | (33) | |
| Change in intrinsic value of outstanding hedging item used to determine | |||
| hedge effectiveness | (7) | 33 | |
| Weighted average foreign currency rate for the year (/£1) | $1.25 | $1.26 | |
| Ineffectiveness recognised in profit or loss | – | – | |
| Cumulative loss remaining in translation reserve | (130) | (137) |
| At 31 March | |||
| 2024 | 2023 | ||
| Natural gas cash flow hedges | £m | £m | |
| Nominal amounts of futures contracts (each contract expressed in 10,000 | mBTU of usage) | 233 | 325 |
Gross carrying amount of outstanding hedged items: assets | 3 | 4 | |
| Gross carrying amount of outstanding hedged items: liabilities | – | (1) | |
| Carrying amount of hedging instrument | (3) | (3) | |
| Hedge ratio | 1:1 | 1:1 | |
| Change in intrinsic value of outstanding hedging instruments used to determine | |||
| hedge effectiveness | (3) | (3) | |
| Change in intrinsic value of outstanding hedging item used to determine hedge effectiveness | 3 | 3 | |
| Ineffectiveness recognised in profit or loss | – | – |
| At 31 March | ||||
| 2024 | 2023 | |||
| Commodity | Commodity | |||
| derivatives | derivatives | |||
| Cash flow hedge reserve | £m | £m | ||
Opening balance | (32) | 50 | ||
Fair value loss in the year | (6) | (2) | ||
| Hedging loss/(gain) transferred to inventory | 4 | (19) | ||
| Fair value gain on cash flow hedges transferred to the income | statement | – | (48) | |
| Deferred tax | (1) | 5 | ||
| Share of other comprehensive expense of joint venture net of | tax | (1) | (18) | |
| Closing balance | (36) | (32) | ||
Cash flows expected to occur 1 : | ||||
| – | within one year | (36) | (29) |
| At 31 March 2024 | ||||||
| Level 1 | Level 2 | Level 3 | Total | |||
| Notes | £m | £m | £m | £m | ||
| Assets at fair value | ||||||
Financial assets at FVPL | 18 | – | – | 22 | 22 | |
Financial assets at FVOCI | 18 | – | – | 6 | 6 | |
| Derivative financial instruments: | ||||||
| – | commodity derivatives | – | – | – | – | |
| Assets at fair value | – | – | 28 | 28 | ||
| Liabilities at fair value | ||||||
| Derivative financial instruments: | ||||||
| – | commodity derivatives | (3) | – | – | (3) | |
| Liabilities at fair value | (3) | – | – | (3) | ||
| At 31 March 2023 | ||||||
| Level 1 | Level 2 | Level 3 | Total | |||
| Notes | £m | £m | £m | £m | ||
| Assets at fair value | ||||||
Financial assets at FVPL | 18 | – | – | 20 | 20 | |
Financial assets at FVOCI | 18 | – | – | 22 | 22 | |
| Derivative financial instruments: | ||||||
| – | commodity derivatives | 3 | – | – | 3 | |
| Assets at fair value | 3 | – | 42 | 45 | ||
| Liabilities at fair value | ||||||
| Derivative financial instruments: | ||||||
| – | commodity derivatives | (4) | – | – | (4) | |
| Liabilities at fair value | (4) | – | – | (4) | ||
| Commodity | Commodity | ||||||
| pricing | pricing | Financial | Financial | ||||
| contracts – | contracts – | assets | assets | ||||
| assets | liabilities | at FVPL | at FVOCI | Total | |||
| £m | £m | £m | £m | £m | |||
At 1 April 2022 | 2 | – | 20 | 26 | 48 | ||
| Income statement: | |||||||
| – | prior year amounts settled | (2) | – | – | – | (2) | |
Other comprehensive income | – | – | – | 3 | 3 | ||
| Re-measurement of non-qualified deferred | compensation arrangements (Note 18) | – | – | (2) | – | (2) | |
Purchases | – | – | 3 | – | 3 | ||
Disposals | – | – | (3) | (7) | (10) | ||
Currency translation differences | – | – | 2 | – | 2 | ||
At 31 March 2023 | – | – | 20 | 22 | 42 | ||
| Income statement: | |||||||
| – | prior year amounts settled | – | – | – | – | – | |
| Other comprehensive income | – | – | – | (17) | (17) | ||
| Re-measurement of non-qualified deferred | compensation arrangements (Note 18) | – | – | 3 | – | 3 | |
| Purchases | – | – | 2 | 1 | 3 | ||
| Disposals | – | – | (3) | – | (3) | ||
| At 31 March 2024 | – | – | 22 | 6 | 28 | ||
| Income | At 31 March 2024 | Income | At 31 March 2023 | |
| statement -/+ | Equity -/+ | statement -/+ | Equity -/+ | |
| £m | £m | £m | £m | |
Sterling/US dollar 10% change | 1 | 37 | 1 | 34 |
Sterling/euro 10% change | – | – | – | – |
| Year ended 31 March | ||
| 2024 | 2023 | |
| Times | Times | |
Net debt/EBITDA 1 | 0.3 | 0.6 |
| At 31 March 2024 | ||||
| < 1 year | 1 – 5 years | > 5 years | ||
| Liquidity analysis | £m | £m | £m | |
Borrowings | – | (222) | (317) | |
Lease liabilities | (11) | (32) | (8) | |
| Interest on borrowings | (19) | (56) | (23) | |
| Trade and other payables | (256) | – | – | |
| Derivative contracts: | ||||
| – | receipts | 65 | – | – |
| – | payments | (65) | – | – |
| Commodity derivatives | (3) | – | – |
| At 31 March 2023 | ||||
| < 1 year | 1 – 5 years | > 5 years | ||
| Liquidity analysis | £m | £m | £m | |
Borrowings | (102) | (226) | (323) | |
Lease liabilities | (14) | (37) | (13) | |
Interest on borrowings | (25) | (66) | (33) | |
Trade and other payables | (365) | – | – | |
| Derivative contracts: | ||||
| – | receipts | 168 | – | – |
| – | payments | (168) | – | – |
Commodity derivatives | (1) | – | – |
| At 31 March | |||
| 2024 | 2023 | ||
| Note | £m | £m | |
Net debt | 28 | 153 | 238 |
| Equity attributable to owners of the Company | 1 238 | 1 189 | |
| Total capital | 1 391 | 1 427 |
At 31 March 2024 | At 31 March 2023 | ||||||
| UK plans* | US plans | Total | UK plans* | US plans | Total | ||
| £m | £m | £m | £m | £m | £m | ||
| Benefit obligations: | |||||||
Funded plans | (622) | (399) | (1 021) | (621) | (433) | (1 054) | |
| Unfunded plans | (3) | (76) | (79) | (4) | (84) | (88) | |
(625) | (475) | (1 100) | (625) | (517) | (1 142) | ||
Fair value of plan assets | 618 | 400 | 1 018 | 616 | 426 | 1 042 | |
| Net deficit | (7) | (75) | (82) | (9) | (91) | (100) | |
| Presented in the statement of financial | |||||||
| position | as: | ||||||
| Retirement benefit surplus | 5 | 24 | 29 | 5 | 13 | 18 | |
| Retirement benefit deficit | (12) | (99) | (111) | (14) | (104) | (118) | |
(7) | (75) | (82) | (9) | (91) | (100) |
| US plans | US plans | |||||
| UK plans | funded | Unfunded* | Total | |||
| £m | £m | £m | £m | |||
Net deficit at 1 April 2023 | (9) | (7) | (84) | (100) | ||
| Income statement: | ||||||
| – | current service costs | – | – | – | – | |
| – | administration costs | (1) | (1) | – | (2) | |
| – | net interest expense US plans | – | 1 | (4) | (3) | |
| Other comprehensive income: | ||||||
| – | actual return higher/(lower) than interest on plan assets | 16 | (4) | – | 12 | |
| – | actuarial gain/(loss): | |||||
| – | changes in financial assumptions | – | 16 | 3 | 19 | |
| – | changes in demographic assumptions | 5 | – | (1) | 4 | |
| – | experience against assumptions | (21) | – | 2 | (19) | |
| Other movements: | ||||||
| – | employer’s contribution | 2 | – | 7 | 9 | |
| – | non-qualified deferred compensation arrangements | – | (3) | – | (3) | |
| – | currency translation differences | 1 | (1) | 1 | 1 | |
| Net deficit at 31 March 2024 | (7) | 1 | (76) | (82) | ||
| US plans | US plans | |||||
| UK plans | funded | unfunded | Total | |||
| £m | £m | £m | £m | |||
At 1 April 2023 | (625) | (433) | (84) | (1 142) | ||
| Income statement: | ||||||
| – | current service costs | – | – | – | – | |
| – | interest costs | (29) | (18) | (4) | (51) | |
| Other comprehensive income: | ||||||
| – | actuarial gain/(loss): | |||||
| – | changes in financial assumptions | – | 16 | 3 | 19 | |
| – | changes in demographic assumptions | 5 | – | (1) | 4 | |
| – | experience against assumptions | (21) | – | 2 | (19) | |
| Other movements: | ||||||
| – | benefits paid | 44 | 30 | 7 | 81 | |
| – | non-qualified deferred compensation arrangements | – | (3) | – | (3) | |
| – | currency translation differences | 1 | 9 | 1 | 11 | |
| At 31 March 2024 | (625) | (399) | (76) | (1 100) | ||
| US plans | US plans | ||||
| UK plans | funded | unfunded | Total | ||
| £m | £m | £m | £m | ||
At 1 April 2023 | 616 | 426 | – | 1 042 | |
| Income statement: | |||||
| – | administration costs | (1) | (1) | – | (2) |
| – | interest gains | 29 | 19 | – | 48 |
| Other comprehensive income: | |||||
| – | actual return higher/(lower) than interest on plan assets | 16 | (4) | – | 12 |
| Other movements: | |||||
| – | employer’s contribution | 2 | – | – | 2 |
| – | benefits paid | (44) | (30) | – | (74) |
| – | currency translation differences | – | (10) | – | (10) |
| At 31 March 2024 | 618 | 400 | – | 1 018 | |
At 31 March 2024 | At 31 March 2023 | ||||
| Principal assumptions | UK | US | UK | US | |
Inflation rate | 3.0%/3.4% | 2.5% | 2.8%/3.3% | 2.5% | |
Expected rate of salary increases | n/a | n/a | n/a | n/a | |
| Expected rate of pension increases: | |||||
| – | deferred pensions | 3.0% | n/a | 2.8% | n/a |
| – | pensions in payment | 3.3% | n/a | 3.2% | n/a |
| Discount rate | 4.8% | 5.0% | 4.8% | 4.6% | |
| Average life expectancy | |||||
| – | male aged 65 now/in 20 years | 20.8/22.4 years | 20.7/23.4 years | 20.9/22.5 years | 20.6/23.4 years |
| – | female aged 65 now/in 20 years | 23.4/25.1 years | 22.6/25.3 years | 23.6/25.2 years | 22.6/25.3 years |
| Increase/(decrease) in obligation | |||
| Impact of | Impact of | ||
| Change in | increase in | decrease in | |
| assumptions | assumption | assumption | |
| +/- | £m | £m | |
Inflation rate 1 | 50 bp | 6 | (37) |
Life expectancy | 1 year | 46 | (46) |
Discount rate | 50 bp | (50) | 54 |
Year ended 31 March 2024 | Year ended 31 March 2023 | |||||
| UK | US | Total | UK | US | Total | |
| £m | £m | £m | £m | £m | £m | |
| Quoted | ||||||
Equities | 3 | – | 3 | 3 | – | 3 |
| Corporate bonds | 2 | – | 2 | 2 | – | 2 |
| Investment funds | 5 | – | 5 | 5 | – | 5 |
| Liability Driven Investments (LDI) | ||||||
| fixed income | – | 396 | 396 | – | 422 | 422 |
| Cash | 6 | – | 6 | 7 | – | 7 |
| Unquoted | ||||||
| Insurance policies | 602 | 4 | 606 | 599 | 4 | 603 |
618 | 400 | 1 018 | 616 | 426 | 1 042 |
| UK plans | US plans | Total | ||
| £m | £m | £m | ||
Weighted average duration (years) | 10.9 | 8.7 | 10.0 | |
| Benefit payments expected: | ||||
| – | within 12 months | 43 | 39 | 82 |
| – | between 1 to 5 years | 175 | 149 | 324 |
| – | between 6 to 10 years | 217 | 167 | 384 |
| Risk | Action taken | |
| Investment | The investment and longevity risks for the main UK scheme have been fully insured through the purchase | |
| and longevity | of a qualifying bulk annuity insurance policy during the year ended 31 March 2020. At 31 March 2024, | |
| risks | £606 | million (2023 – £603 million) of the benefit obligation was fully matched by qualifying insurance |
| benefit plans in the US are predominantly held in fixed interest security type investments, as a result of the | policies that also mitigate longevity and investment risks. The remaining assets of the funded defined | |
| de-risking initiatives through the sale of equities and some investment funds. The Group therefore uses | ||
| an asset matching strategy to hedge the liability with cash flows and credit profiles similar to the specific | pension plan liabilities, and which are designed to match the movement in the balance sheet liabilities. | |
| No | leverage is used and there are no derivatives used in the portfolio. Note that it is not possible to | |
| precisely match the liability movements as it is not possible to construct a portfolio that generates an | ||
| identical yield to AA Corporate Bond yields that are used to value the liabilities under IFRS. | ||
| Interest rate | The bulk annuity insurance policy has nullified the interest rate risk for the main UK scheme. For the US | |
| risk | funded plans, the Group seeks to ensure that, as far as practicable, the investment portfolios are invested | |
| in securities with maturities and in currencies that match the expected future benefit payments as they | ||
| fall | due. | |
| Inflation risk | Inflation risk for the main UK scheme has also been nullified due to the bulk annuity policy. The deferred | |
| pensions and pensions in payment in the US funded plans do not attract inflation increases. Some inflation | risk exists in relation to the employee members’ benefits which is mitigated by holding index-linked | |
| government bonds and corporate bonds. | ||
Year ended 31 March 2024 | Year ended 31 March 2023 | |||
| Weighted | Weighted | |||
| average | average | |||
| exercise | exercise | |||
| Awards | price | Awards | price | |
| (number) | (pence) | (number) | (pence) | |
Outstanding at 1 April | 9 574 032 | 16p | 10 407 889 | 12p |
Granted | 3 399 485 | 20p | 3 457 036 | 16p |
| Exercised | (1 966 442) | 16p | (1 353 110) | 15p |
| Lapsed | (1 526 182) | 27p | (2 937 783) | 4p |
| Outstanding at 31 March | 9 480 893 | 16p | 9 574 032 | 16p |
Exercisable at 31 March | 101 675 | 187p | 71 415 | 243p |
Year ended 31 March 2024 | Year ended 31 March 2023 | |||
PSP | Sharesave | PSP | Sharesave | |
Fair value at grant date | 629p | 180p | 694p | 211p |
Exercise price | – | 512p | – | 571p |
| Principal assumptions: | ||||
| Share price on grant date | 754p | 644p | 805p | 730p |
| Expected life of the awards | 3 years | 3.3/5.3 years | 3 years | 3.3/5.3 years |
| Risk-free interest rate | 4.94% 4.07%/3.92% | 1.85% | 3.22%/3.16% | |
| Dividend yield on the Company’s shares | 2.55% | 3.00% | 2.26% | 2.49% |
| Volatility of the Company’s shares | 25% | 25% | 25% | 25% |
| Comparator share price volatility* | 24%-33% pa | – | 22%-36% pa | – |
| Comparator correlation* | 25% | – | 25% | – |
At 31 March 2024 | At 31 March 2023 | |||
| Weighted | Weighted | |||
| average | average | |||
| contractual | contractual | |||
| Awards | life | Awards | life | |
| Exercise price | (number) | (months) | (number) | (months) |
Nil | 9 204 900 | 15.0 | 9 299 770 | 26.6 |
400p to 799p | 275 993 | 36.5 | 274 262 | 33.9 |
| Total | 9 480 893 | 15.6 | 9 574 032 | 26.8 |
| Restructuring | Litigation | |||
| Insurance | and closure | and other | ||
| provisions | provisions | provisions | Total | |
| £m | £m | £m | £m | |
At 1 April 2022 | 5 | – | 18 | 23 |
Provided in the year | 17 | – | 8 | 25 |
Released in the year | (9) | – | (13) | (22) |
Utilised in the year | (6) | – | (3) | (9) |
Currency translation differences | – | – | 1 | 1 |
At 31 March 2023 | 7 | – | 11 | 18 |
Provided in the year | 10 | 3 | 1 | 14 |
Released in the year | (2) | – | (3) | (5) |
| Utilised in the year | (8) | (2) | (3) | (13) |
| Currency translation differences | – | – | – | – |
| At 31 March 2024 | 7 | 1 | 6 | 14 |
| At 31 March | |||
| 2024 | 2023 | ||
| £m | £m | ||
| Provisions are expected to be utilised as follows: | |||
| – | within one year | 12 | 13 |
| – | after more than one year but before five years | 2 | 5 |
| Total | 14 | 18 |
| At 31 March | |
| 2023 | |
| Goodwill | £m |
| Total consideration | 188 |
| Less: fair value of net assets acquired | (93) |
| Goodwill | 95 |
| At 31 March | |
| 2023 | |
| Cash flows | £m |
| Total consideration | 188 |
| Less: net cash acquired | (4) |
| Acquisition of business, net of cash acquired | 184 |
| Book | |||
| value on | Fair value | Total fair | |
| acquisition | adjustment | value | |
| Fair value of net assets acquired | £m | £m | £m |
Intangible assets (customer relationships, technology/know-how) | – | 90 | 90 |
Property, plant and equipment | 12 | 7 | 19 |
| Inventories | 4 | 1 | 5 |
| Trade and other receivables | 5 | – | 5 |
| Cash and cash equivalents | 4 | – | 4 |
| Trade and other payables | (6) | – | (6) |
| Deferred tax liabilities | – | (24) | (24) |
| Net assets on acquisition | 19 | 74 | 93 |
| Year ended 31 March | ||
| 2024 | 2023 | |
| £m | £m | |
| Sales of goods and services to joint ventures and other income | 39 | 47 |
| Purchases of goods and services from joint ventures | 243 | 302 |
| Receivables due from joint ventures | 11 | 16 |
| Payables due to joint ventures | 1 | 18 |
Company name | Registered address | |
United Kingdom 1 | ||
Astaxanthin Manufacturing Limited | 5 Marble Arch, London W1H 7EJ, UK | |
| G.C. Hahn and Company Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Hahntech International Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Export Holdings Limited 2 | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Group Services Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Holdings Americas Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Holdings Limited 3 | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Mold UK Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Industries Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle International Finance PLC 2 | 5 Marble Arch, London W1H 7EJ, UK | |
| Tate & Lyle Investments America Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Investments Brazil Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Investments Limited 2,3 | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle L.P. | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Overseas Limited | 5 Marble Arch, London W1H 7EJ, UK | |
| Tate & Lyle Pension Trust Limited | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Technology Limited 2 | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle UK Limited 2 | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Ventures II LP (99.5%) | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Ventures Limited 2 | 5 Marble Arch, London W1H 7EJ, UK | |
Tate & Lyle Ventures LP (99.5%) | 5 Marble Arch, London W1H 7EJ, UK | |
| Argentina | ||
Tate & Lyle Argentina SA 4 | San Martín 140, 14th Floor, City of Buenos Aires, Argentina | |
| Australia | ||
Tate & Lyle ANZ Pty Limited | Building 2, 1425 Boundary Road, Wacol QLD 4076, Australia | |
| Belgium | ||
Tate & Lyle Services (Belgium) N.V. 2 | Industrielaan 4 box, 10-11, 9320 Aalst, Belgium | |
| Bermuda | ||
Tate & Lyle Management & Finance Limited | Aon Point House, 6 Front Street, Hamilton HM11 Bermuda |
Company name | Registered address | |
| Brazil | ||
| Tate & Lyle Gemacom Tech Indústria e Comércio S.A. | Rua Bruno Simili No. 380, Distrito Industrial, City of Juiz de | |
| Fora, State of Minas Gerais, 36092-050, Brazil | ||
| Tate & Lyle Solutions Brasil Limitada | Rua Dr. Rubens Gomes Bueno, No. 691, Torre Sigma, | |
10 th | floor, Bairro Várzea de Baixo, 04730-903, Brazil | |
| British Virgin Islands | ||
SGF (Asia) Co., Limited | Kingston Chambers, PO Box 173, Road Town, Tortola, | |
| British | Virgin Islands | |
SGF Investment Co., Limited | Kingston Chambers, PO Box 173, Road Town, Tortola, | |
| British | Virgin Islands | |
| Canada | ||
Tate & Lyle Solutions Canada Limited | Suite 300, 77 Westmorland Street, Fredericton, NB E3B 4Y9, | |
| Canada | ||
| Cayman Islands | ||
Sweet Green Fields Group Co., Limited | PO Box 309, Ugland House, Grand Cayman, KY1-1104, | |
| Cayman Islands | ||
| Chile | ||
Tate & Lyle Chile Commercial Ltda | Isidora Goyenechea 2800, Piso 43, Las Condes, Santiago, | |
| Chile | ||
| China | ||
| Quantum High Tech (Guangdong) Biological Co., Ltd | 133 | Gaoxin Xi Road, Hi-Tech Zone, Jiangmen City, |
| Guangdong, China | ||
| Sweet Green Fields Co., Limited | Anji Economic Development Zone, Health Medicine Industry | |
| Garden, Huzhou, Zhejiang, China | ||
| Tate & Lyle Trading (Shanghai) Co. Ltd | Room 1401, | Building 11, No. 1582, Gumei Road, Xuhui District, |
Shanghai, 200233, | China | |
| G.C. Hahn & Co. Food Stabiliser Business (Shanghai) Ltd | Unit A, Room 1301, Building 11, No. 1582, Gumei Road, Xuhui | |
| District, Shanghai, 200233, China | ||
| Tate & Lyle Food Ingredients (Nantong) Company Limited | New & Hi-Tech Industrial Development District, Rudong | |
| county, Nantong city, 226400, China | ||
Company name | Registered address | |||
| Colombia | ||||
Tate & Lyle Colombia S.A.S. 4 | Calle 11 #100-121 Of 309, Cali, Colombia | |||
| Costa Rica | ||||
Tate & Lyle Costa Rica Limitada | San Jose Merced, Edificio Torre Mercedes, Piso Octavo, | |||
| Oficinas De CDO Auditores, Costa Rica | ||||
| Croatia | ||||
G.C. Hahn & Co. d.o.o. | Radni ē ka cesta 80, Zagreb, 10 000, Croatia | |||
| Egypt | ||||
Tate & Lyle Egypt LLC | 87 Street 9, Maadi, Cairo, Egypt | |||
| France | ||||
Tate & Lyle Ingredients France S.A.S. | 3-5 Rue Saint-Georges, | 75009, | Paris, France | |
| Germany | ||||
G.C. Hahn & Co. Stabilisierungstechnik GmbH | Roggenhorster Strasse 31, 23556, Lübeck, Germany | |||
G.C. Hahn & Co. Cooperationsgesellschaft mbH | Roggenhorster Strasse 31, 23556, Lübeck, Germany | |||
Tate & Lyle Germany GmbH | Roggenhorster Strasse 31, 23556, Lübeck, Germany | |||
| Gibraltar | ||||
Tate & Lyle Insurance (Gibraltar) Limited | Suite 913, Europort, Gibraltar | |||
| Greece | ||||
Tate & Lyle Greece A.E. | 69 K. N Papadaki, Thessaloniki, 54248 Greece | |||
| Hong Kong | ||||
| Quantum High Tech (HK) Biological Co., Ltd | 31F Tower Two, Times Square, Matheson Street, Hong Kong | |||
Sweet Green Fields International Co., Limited | 2701, | 27th Floor, Central Plaza, 18 Harbour Road, Wanchai, | ||
| Hong Kong | ||||
| Italy | ||||
Tate & Lyle Italia S.P.A. | Via Verdi, 1-CAP 20002 Ossona, Milano, Italy | |||
| Indonesia | ||||
| PT Tate and Lyle Indonesia | Jagat Office Building, Lantai 2 Unit B, Jl. Tomang Raya No. | |||
| 28-30, Jakarta Barat, 11430, Indonesia | ||||
| Ivory Coast | ||||
Tate & Lyle Ivory Coast 4 | Abidjan Cocody 2, Plateaux 01, BP 659 ABJ 01, Côte d’Ivoire | |||
| Japan | ||||
Tate & Lyle Japan KK | 2F Oak Minami-Azabu Building, 3-19-23 Minami-Azabu, | |||
| Minato-ku, Tokyo, Japan | ||||
| Lithuania | ||||
UAB G.C. Hahn & Co. | Vito Gerulai ē io str. 10-101, LT-08200, Vilnius, Lithuania | |||
| Mexico | ||||
| Tate & Lyle México, S. de R.L. de C.V. | Piso 2, Av. Universidad 749, Col del Valle Sur, Ciudad de | |||
México, 03100, | México | |||
Mexama, S.A. de C.V. 4 (65%) | Calle lago de tequesquitengo, No 111 Col. Cuahutemoc C.P. | |||
62430, | Morelos, México | |||
Talo Services de Mexico, S.C. 4 | Piso 2, Av. Universidad 749, Col del Valle Sur, Ciudad de | |||
México, 03100, | México | |||
Company name | Registered address |
| Morocco | |
T&L Casablanca S.A.R.L. | 22, Rue du Parc, Casa Théâtre Centre, Anfa, Casablanca, |
| Morocco | |
| Netherlands | |
Nederlandse Glucose Industrie B.V. | Lagendijk 5, Koog aan de Zaan, 1541KA, The Netherlands |
Tate & Lyle Netherlands B.V. | Lagendijk 5, Koog aan de Zaan, 1541KA, The Netherlands |
| Poland | |
Tate & Lyle Global Shared Services Sp.z o.o. | Ul. Piotrkowska 157A Łódź 90-440 Poland |
| Singapore | |
Tate & Lyle Asia Pacific Pte. Ltd. | 3 Biopolis Drive, #05-11-16 Synapse, 138623 Singapore |
| Slovakia | |
Tate & Lyle Boleráz s.r.o. | 114, Boleráz, 91908, Slovakia |
Tate & Lyle Slovakia s.r.o. | 114, Boleráz, 91908, Slovakia |
| South Africa | |
Tate and Lyle South Africa Proprietary Limited | 1 Gravel Drive, Kya Sand Business Park, Kya Sand, 2163, |
| South Africa | |
| Spain | |
G.C. Hahn Estabilizantes y Tecnologia para Alimentos | Calle Príncipe de Vergara 112, Planta Cuarta, 28002, Madrid, |
| Spain | |
Ebromyl S.L. | Ps. de la Constitución 10, Entlo. Dcha., 50008, Zaragoza, |
| Spain | |
| Sweden | |
Tate & Lyle Sweden AB | Mäster Samuelsgatan 17, Box 1432, 111 84, Stockholm, |
| Sweden | |
| Thailand | |
Chaodee Modified Starch Co., Ltd (95.3491%) | No. 345, Moo 14, Hin Dat Subdistrict, Dan Khun Thot District, |
| Nakhom Ratchasima Province, Thailand | |
Tate & Lyle Trading (Thailand) Limited | No. 345, Moo 14, Hin Dat Subdistrict, Dan Khun Thot District, |
| Nakhom Ratchasima Province, Thailand | |
| Türkiye | |
Tate and Lyle Turkey Gıda Hizmetleri Anonim Şirketi | Esentepe Mah., Büyükdere Cad., 193 Plaza Kat: 2 193/235A14 |
| Şişli, İstanbul, Türkiye | |
| Ukraine | |
PII G.C. Hahn & Co. Kyiv 4 | 15 Zahorodnia Street, Kyiv, 03150, Ukraine |
| United Arab Emirates | |
Tate & Lyle DMCC | Unit JLT-PH2-RET-X5, Detached Retail X5, Jumeirah Lakes |
| Towers, Dubai, United Arab Emirates |
Company name | Registered address | |
| US | ||
Staley Holdings LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Staley International Inc. | 1209 | North Orange Street, Wilmington, DE 19801, US |
Sweet Green Fields USA LLC | 11 Bellwether Way, Suite 305, Bellingham WA 98225, US | |
Tate & Lyle Finance LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
TLHUS, Inc. | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Sucralose LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
TLI Holding LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Malic Acid LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Sugar Holdings, Inc. | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Americas LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Citric Acid LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Solutions USA LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle PP Americas LLC | 1209 | North Orange Street, Wilmington, DE 19801, US |
Tate & Lyle Domestic International Sales II Corporation | 1209 | North Orange Street, Wilmington, DE 19801, US |
Company name | Registered address | |
| US | ||
Primary Products Investments LLC (49.7%) | 1209 | North Orange Street, Wilmington, DE 19801, US |
Company name | Registered number |
Tate & Lyle Export Holdings Limited | 10021479 |
Tate & Lyle Group Services Limited | 00343970 |
Tate & Lyle Holdings Americas Limited | 06390829 |
Tate & Lyle Holdings Limited | 00471470 |
Tate & Lyle Industries Limited | 00699090 |
Tate & Lyle Investments America Limited | 10384878 |
Tate & Lyle Investments Brazil Limited | 05399545 |
Tate & Lyle Technology Limited | 05994725 |
Tate & Lyle UK Limited | 09092139 |
Tate & Lyle Ventures Limited | 03403518 |